International Journal of Stem Cells : eISSN 2005-5447

Table. 1.

Table. 1.

Advantages and drawbacks of cell products used for peripheral artery disease

Cell therapy types Advantages Drawbacks
Bone-Marrow derived Mononuclear Cells (BMMNC)

- Most widely researched cell product for PAD.

- Several meta-analyses showed improvement in ABI, TcPO2, pain scores, and ulcer healing in BMMNC treated patients (9092).

- Availability of long term safety result (3 years) (109).

Risk and complications during bone marrow aspiration.
Peripheral Blood derived Mononuclear Cells (PBMNC)

- Head-to-head comparison with BMMNC showed similar benefits (65).

- Recent meta-analysis showed PBMNC, but not BMMNC are able to reduce risk of major amputation and improve ulcer healing (88).

- Availability of long term safety result (1 year) (101).

- Risk and complications during G-CSF/GM-CSF administration (105).

- Efficacy of stem cells mobilizations are significantly influenced by race, ethnics, and disease status (62).

Mesenchymal Stem Cells (MSC)

- Promising result from preclinical and clinical studies.

- Able to be isolated and expanded to achieve consistentand desirable dose.

- Allow larger-scale manufacturing with good quality control to produce an ‘off the-shelf’ cellular products.

- Possibility of allogeneic therapy due to its non or low-antigenic properties.

- Risk and complications during bone marrow aspiration (in BMMSC).

- Reports of potential role of MSC in tumor development.

- High variability of cell products between protocols and research facility.

- Relatively more expensive.

International Journal of Stem Cells 2021;14:21-32 https://doi.org/10.15283/ijsc20088
© 2020 International Journal of Stem Cells